Antroquinonol ( HOCENA ), new oral drug clinical trial in Covid-19, AML, Lung Cancer, NSCLC, Pancreatic Cancer-Pandemic, Oncology

Model: Antroquinonol ( HOCENA )

Booth No: R309

Characteristic

Antroquinonol (HOCENA) is a new small molecule drug (NCE) and distinguished from other developing drugs for COVID-19 by its convenient oral administration design and multi-functional effects on anti-viral, anti-inflammation and anti-fibrosis characteristics revealed by studies.
Golden Biotechnology Corporation (GBC, GoldenBiotech) (TPEx: 4132), founded in 2002, is a leading global biopharmaceutical company. GoldenBiotech focuses on discovery and clinical development of innovative therapeutic new drugs (NCE), and dedicated to improving quality of life by developing products that prevent and treat diseases.
GoldenBiotech discovered from its own screening platforms Antroquinonol® (trade name HOCENA® ), which has been granted more than 140 patents worldwide for its structure, preparation and applications in oncology, cardio-metabolic syndromes, autoimmune diseases, neurodegenerative diseases and infectious diseases. Since 2013, Antroquinonol® was authorized Phase II clinical trial on NSCLC by US FDA and Taiwan FDA and trial completed in 2019. The clinical trials on acute myeloid leukemia (AML) has also completed in 2020, and the multi-national trials on pancreatic cancer and COVID-19 expected to accomplish in mid-2021. Orphan Drug Designations (ODD) were obtained in treatment of pancreatic cancer (US #14-4608 & EU), AML (US#15-4763) and hepatocellular carcinoma (US#15-4881).
GoldenBiotech has completed the Phase 2 multi-national COVID-19 clinical trial in the US, Peru and Argentina and the trial has been unblinded clinical results in Jan. 2022.
Antroquinonol® is an oral new drug which exhibits a broad spectrum of activities against malignancies in-vivo and in-vitro, and offers a better solution than the single-action compounds the industry developed so far. Antroquinonol’s multiple, simultaneous, and synergistic actions enable positive outcomes. Antroquinonol® can be used as a monotherapy, combination- or adjuvant-therapy to complement other drugs, or as a best supportive care. Demonstrated safety profile and efficacy make Antroquinonol® an ideal asset in treating diseases and improving overall quality of life of patients.